Assessing Second‐Line Treatment Strategies and Outcomes in Epidermal Growth Factor Receptor ( <scp>EGFR</scp> ) Oncogene‐Driven Stage <scp>IV</scp> Non‐Small Cell Lung Cancer, Following a First‐Line <scp>EGFR</scp> ‐ <scp>TKI</scp> Therapy
Using real-world data from EnRICH, this represents the largest retrospective analysis of this cohort in Australia and largely predates first-line Osimertinib use. Findings reveal a trend toward second-line Osimertinib use, even after first-line TKI, without significant differences in survival. There, however, remains significant heterogeneity in approaches. The lack of robust second-line data, however, highlights the need for investigating novel therapeutic approaches.
Authors
- Bernadette Brown (ORCID: https://orcid.org/0000-0003-2851-1809)
- Venessa Chin (ORCID: https://orcid.org/0000-0002-4630-4451)
- Robert John Simes (ORCID: https://orcid.org/0000-0002-3740-7563)
- Michael Boyer (ORCID: https://orcid.org/0000-0002-0452-2987)
- M. Maddula (ORCID: https://orcid.org/0009-0003-4819-9397)
- Annelise Decaria (ORCID: https://orcid.org/0009-0005-2646-9311)
Institutions
- The University of Sydney (AU)
- Garvan Institute of Medical Research (AU)
- UNSW Sydney (AU)
- St Vincent's Hospital Sydney (AU)
- Chris O’Brien Lifehouse (AU)
- The Kinghorn Cancer Centre (AU)
- National Health and Medical Research Council (AU)
Publication Details
- Journal
- Cancer Reports
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/cnr2.70428
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Cancer Australia
- Lung Foundation Australia
- National Health and Medical Research Council